Monitor Auvelity's launch in Alzheimer's agitation (June 2026) as the primary near-term catalyst; revenue growth trajectory remains strong, but rising SG&A expenses and EPS miss suggest caution on margin expansion. Focus on prescription trends and payer coverage updates.
AXSM drugs
AXSM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 4 $223.70entry
- T+1 · 7mo ago −0.29%α −1.08% · $223.06
- T+5 · 6mo ago −3.23%α −6.17% · $216.47
- T+20 · 6mo ago +2.93%α −2.72% · $230.25
- T+60 · 4mo ago +1.66%α −0.19% · $227.42
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Axsome reported Q1 2026 revenue of $191.2M (57% YoY growth, slight beat vs $190.7M consensus), but GAAP EPS of -$1.26 missed the -$0.86 consensus by 46.5% due to higher SG&A and R&D costs. The recent FDA approval of Auvelity for Alzheimer's agitation is a key catalyst, but widening losses and rising expenses temper optimism.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue $191.2M, +57% YoY vs $121.5M
- AUVELITY revenue $153.2M, +59% YoY; ~223,000 prescriptions written
- SUNOSI revenue $33.9M, +34% YoY; SYMBRAVO revenue $4.1M
- GAAP net loss $(64.5M) or $(1.26)/share vs $(59.4M) or $(1.22)/share in Q1 2025
- FDA approved AUVELITY for Alzheimer's disease agitation in April 2026; full launch expected June 2026
- Cash and equivalents $305.1M at March 31, 2026
Financial Impact
Revenue grew 57% YoY to $191.2M, but net loss widened to $(64.5M) from $(59.4M) due to increased SG&A and R&D spending.
Risk Factors
- SG&A expenses grew 53% YoY, outpacing revenue growth and pressuring margins
- Net loss per share worsened to $(1.26), missing consensus by 46.5%
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3286568 |
Track record
26 reports on AXSM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers